Urinary profile of methylprednisolone and its metabolites after oral and topical administrations

Xavier Matabosch, Oscar J. Pozo, Núria Monfort, Clara Pérez-Mañá, Magi Farré, Josep Marcos, Jordi Segura, Rosa Ventura

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

Methylprednisolone (MP) is prohibited in sports competitions when administered by systemic routes; however its use by topical administration is allowed. Therefore, analytical approaches to distinguish between these different administration pathways are required. A reporting level of 30 ng/mL was established for this purpose. However, the suitability of that reporting level for MP is not known. In the present work, excretion profiles of MP and different metabolites after oral and topical administrations have been compared. A method for the quantification of MP and the qualitative detection of fifteen previously reported metabolites has been validated. The method involved an enzymatic hydrolysis, liquid-liquid extraction and analysis by liquid chromatography coupled to tandem mass spectrometry. The method was found to be linear, selective, precise and accurate. The high sensitivity (limit of detection 0.1 ng/mL) and linear range (0.1-250 ng/mL) achieved allowed for the quantification of MP at both the low concentrations present after topical administration and the high concentrations detected after oral intake. The method was applied to samples collected after oral (4 or 40 mg) and topical administration (10 mg of MP aceponate/day for 5 consecutive days) to healthy volunteers. After oral administration, MP and all metabolites were detected in urines collected up to at least 36 h. Only MP and five metabolites were detected in samples obtained after topical treatment. As expected, concentrations of MP after topical administration were well below current reporting level (30 ng/mL), however 3 out of 4 samples in range 8-24 h after the low oral dose (4 mg) were also below that concentration. Taking into account metabolites detected after both administration routes, metabolites 16β,17α,21-trihydroxy- 6α-methylpregna-1,4-diene-3,11,20-trione (M8) and 17α,20α,21- trihydroxy-6α-methylpregna-1,4-diene-3,11-dione (M11) are best markers to differentiate between topical and oral administrations. Their signals after topical administration were lower than those obtained in the first 48 h after all oral doses. © 2013 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)214-221
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume138
DOIs
Publication statusPublished - 22 Jul 2013

Keywords

  • Doping
  • LC-MS/MS
  • Metabolites
  • Methylprednisolone
  • Routes of administration

Fingerprint

Dive into the research topics of 'Urinary profile of methylprednisolone and its metabolites after oral and topical administrations'. Together they form a unique fingerprint.

Cite this